These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 38090577)

  • 1. Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights.
    Pu Z; Wang TB; Mou L
    Front Immunol; 2023; 14():1310285. PubMed ID: 38090577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
    Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
    Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
    J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies.
    Castellanos-Rueda R; Di Roberto RB; Schlatter FS; Reddy ST
    Trends Biotechnol; 2021 Dec; 39(12):1308-1320. PubMed ID: 33832782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Imaging of CAR T Immunotherapy to Solid Tumors: In Terms of Biodistribution, Viability, and Cytotoxic Effect.
    Ren M; Yao B; Han B; Li C
    Adv Biol (Weinh); 2023 Jun; 7(6):e2200293. PubMed ID: 36642820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
    Yu T; Yu SK; Xiang Y; Lu KH; Sun M
    Front Immunol; 2022; 13():936496. PubMed ID: 35903099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
    Qin Y; Xu G
    Front Immunol; 2022; 13():1053120. PubMed ID: 36569859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomaterials for chimeric antigen receptor T cell engineering.
    Niu H; Zhao P; Sun W
    Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.